Bedoradrine: Preliminary Phase Ib data

Preliminary data from the double-blind, placebo-controlled, U.S. Phase Ib MN-221-CL-012 trial in 25 patients with stable, moderate to severe COPD showed that 6 injections of 1,200 µg IV MN-221 over 4 days produced no clinically significant safety concerns. Additionally, preliminary efficacy results showed that MN-221 led to moderate improvements in FEV1 vs. placebo. Transient arrhythmias led to discontinuation of MN-221 on day 1 in 2 patients with pre-existing heart disorders. ...